PPP2CA mutation and deep deletion events occur in 0.4–1.4% of patients with prostate cancer (Tables S1–S3), further highlighting the diversity of genetic aberrations in AKT regulators that could promote oncogenic PI3K signaling. This evidence concerns the gene PIK3CB and prostate carcinoma.